THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS) and a stem cell therapy for diabetes, today announced that on June 3, 2009, the Company received notice that the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“NASDAQ”) has determined to grant the Company an extension to regain compliance with Listing Rule 5550(b)(1) (“Rule”) and continue the listing of the Company’s securities on The NASDAQ Capital Market. The Company’s continued listing on NASDAQ is subject to the condition that the Company provide written evidence of compliance with the $2.5 million stockholders’ equity requirement set forth in the Rule by no later than August 3, 2009 and demonstrate compliance in its periodic filing report for the quarter ending September 30, 2009. The Staff’s determination follows the Company’s previous disclosure on April 20, 2009 regarding its non-compliance with the minimum stockholders’ equity requirement.
